ARTICLE | Finance

Regulatory milestones

Highlights of weekly biotech stock moves

September 6, 2010 7:00 AM UTC

Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.86 (11%) to $9.03 last week after FDA accepted for filing and granted Priority Review to an NDA for Iluvien to treat diabetic macular edema (DME). The company has rights to the injectable fluocinolone acetonide insert from pSivida Corp. (NASDAQ:PSDV; ASX:PVA). pSivida gained $0.20 to $3.51 on NASDAQ, and was off A$0.10 to A$3.64 on the Australian Securities Exchange.

Biofrontera AG (Xetra:B8F) was off €0.25 (12%) to €1.90 last week after submitting an MAA in Europe for BF-200 ALA to treat actinic keratosis. BF-200 ALA is a photodynamic therapy comprising nanoemulsion BF-200 with 5-aminolevulinic acid (ALA) photosensitizer followed by red light illumination...